Centrosome Protein 78 Is Overexpressed in Muscle-Invasive Bladder Cancer and Is Associated with Tumor Molecular Subtypes and Mutation Signatures

被引:1
|
作者
Huang, Xiaoli [1 ,2 ]
Yan, Yang [3 ]
Wei, Rong [2 ]
Liu, Hu [2 ]
Zhu, Xingchen [2 ]
Bi, Dexi [2 ]
Wei, Qing [1 ,2 ]
Yao, Xudong [3 ]
机构
[1] Anhui Med Univ, Shanghai Clin Coll, Dept Pathol, Hefei, Anhui, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Pathol, Sch Med, Shanghai, Peoples R China
[3] Tongji Univ, Shanghai Peoples Hosp 10, Dept Urol, Sch Med, Shanghai, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2020年 / 26卷
基金
中国国家自然科学基金;
关键词
Cell Cycle; Centrosome; Mutation; Urinary Bladder Neoplasms; CELL; EXPRESSION;
D O I
10.12659/MSM.925197
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Centrosome aberrations have long been linked to tumorigenesis. Centrosome protein 78 (CEP78) is a centrosome component that is required to regulate the cell cycle, but its role in bladder cancer has not been elucidated. Material/Methods: Real-time quantitative polymerase chain reaction and immunohistochemistry were used to examine the expression of CEP78 in bladder cancer tissues and adjacent non-cancer tissues. Results: Analysis of the RNA-Seq data from the TCGA (The Cancer Genome Atlas) MIBC cohort (n=408) revealed that CEP78 was overexpressed in tumor tissues, which was confirmed with fresh-frozen and formalin-fixed paraffin-embedded specimens collected from 28 and 33 MIBC patients, respectively, in the present study. The clinicopathological relevance of CEP78 was further investigated. High CEP78 expression was found to be correlated with non-papillary histological type, luminal, basal-squamous and neuronal molecular subtypes, TP53 mutation, RB1 mutation, wild-type FGFR3, PPARG fusion and amplification, high total number of single-nucleotide variants, and high neoantigen load, but it was not associated with tumor stages or overall survival. Conclusions: The results of this study suggest that CEP78 plays in a role in promoting the development of MIBC and could be a novel diagnostic and therapeutic target.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] "Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes
    Pietzak, Eugene J.
    Al-Ahmadie, Hikmat
    Walasek, Aleksandra
    Bajorin, Dean F.
    Rosenberg, Jonathan E.
    Bochner, Bernard H.
    Solit, David B.
    Iyer, Gopa
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S642 - S644
  • [22] Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer
    Zhou, Lin
    Xu, Bin
    Liu, Yushan
    Wang, Zhong
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [23] Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer
    Miyamoto, David T.
    Mouw, Kent W.
    Feng, Felix Y.
    Shipley, William U.
    Efstathiou, Jason A.
    LANCET ONCOLOGY, 2018, 19 (12): : E683 - E695
  • [24] Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer
    Raquel Carrasco
    Mercedes Ingelmo-Torres
    Ascensión Gómez
    Fiorella L. Roldán
    Natalia Segura
    María José Ribal
    Antonio Alcaraz
    Laura Izquierdo
    Lourdes Mengual
    World Journal of Urology, 2022, 40 : 2033 - 2039
  • [25] Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer
    Carrasco, Raquel
    Ingelmo-Torres, Mercedes
    Gomez, Ascension
    Roldan, Fiorella L.
    Segura, Natalia
    Jose Ribal, Maria
    Alcaraz, Antonio
    Izquierdo, Laura
    Mengual, Lourdes
    WORLD JOURNAL OF UROLOGY, 2022, 40 (08) : 2033 - 2039
  • [26] Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer
    Lorenzo Soriano, Laura
    Ordaz Jurado, Guzman
    Pontones Moreno, Jose Luis
    Villarroya Castillo, Sara
    Hernandez Giron, Soraya
    Saez Moreno, Ivan
    Ramos Soler, David
    UROLOGY, 2019, 130 : 93 - 98
  • [27] Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes
    Ruan, Jia-Ling
    Hsu, Jong-Wei
    Browning, Richard J.
    Stride, Eleanor
    Yildiz, Yesna O.
    Vojnovic, Borivoj
    Kiltie, Anne E.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (03): : 239 - 247
  • [28] Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
    Seiler, Roland
    Ashab, Hussam Al Deen
    Erho, Nicholas
    van Rhijn, Bas W. G.
    Winters, Brian
    Douglas, James
    Van Kessel, Kim E.
    van de Putte, Elisabeth E. Fransen
    Sommerlad, Matthew
    Wang, Natalie Q.
    Choeurng, Voleak
    Gibb, Ewan A.
    Palmer-Aronsten, Beatrix
    Lam, Lucia L.
    Buerki, Christine
    Davicioni, Elai
    Sjodahl, Gottfrid
    Kardos, Jordan
    Hoadley, Katherine A.
    Lerner, Seth P.
    McConkey, David J.
    Choi, Woonyoung
    Kim, William Y.
    Kiss, Bernhard
    Thalmann, George N.
    Todenhofer, Tilman
    Crabb, Simon J.
    North, Scott
    Zwarthoff, Ellen C.
    Boormans, Joost L.
    Wright, Jonathan
    Dall'Era, Marc
    van der Heijden, Michiel S.
    Black, Peter C.
    EUROPEAN UROLOGY, 2017, 72 (04) : 544 - 554
  • [29] Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis
    Schallenberg, Simon
    Dragomir, Mihnea-Paul
    Anders, Philipp
    Ebner, Benedikt
    Volz, Yannic
    Eismann, Lennert
    Rodler, Severin
    Casuscelli, Jozefina
    Buchner, Alexander
    Klauschen, Frederick
    Stief, Christian
    Horst, David
    Schulz, Gerald Bastian
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 788 - 798
  • [30] Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy
    da Costa, Jose Batista
    Gibb, Ewan A.
    Nykopp, Timo K.
    Mannas, Miles
    Wyatt, Alexander W.
    Black, Peter C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 287 - 294